60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Sell (E+) Rating at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by investment analysts at Weiss Ratings in a research note issued to investors on Thursday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on SXTP. Ascendiant Capital Markets upped their price objective on 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the company a “buy” rating in a research note on Monday, June 2nd. Wall Street Zen downgraded 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.32 on Thursday. The firm has a market cap of $1.94 million, a price-to-earnings ratio of -0.03 and a beta of 2.71. 60 Degrees Pharmaceuticals has a 52 week low of $1.24 and a 52 week high of $12.70. The firm has a 50-day moving average price of $1.89 and a two-hundred day moving average price of $2.26.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.01). The business had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.32 million. As a group, sell-side analysts forecast that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.